SOPHROSYNE CAPITAL LLC
Q4 2013 13F-HR Holdings
Net value change ($000)
—
New positions
64
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| BIOTELEMETRY, INC. | 9,781 | — |
| Zeltiq Aesthetics Inc | 9,623 | — |
| MSTR | 7,411 | — |
| LSAK | 6,169 | — |
| CALX | 6,163 | — |
| PAIN THERAPEUTICS INC | 6,147 | — |
| ALCOBRA LTD | 5,768 | — |
| ARAY | 4,608 | — |
| BIODELIVERY SCIENCES INTERNATIONAL INC | 4,093 | — |
| MEETME INC | 4,046 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|